Alzheimer's

Cognito Therapeutics, an MIT startup co-founded by Prof. Li-Huei Tsai and Prof. Ed Boyden, has developed a headset that uses light and sound to slow the cognitive decline in Alzheimer’s patients, reports Emily Mullin for Wired. “Cognito’s headset, dubbed Spectris, delivers flashing lights and sounds through a pair of connected glasses and headphones to stimulate gamma waves in the brain” writes Mullin. “Different types of brain waves have different paces, or frequencies. Gamma waves are fast-frequency brain waves associated with thinking skills and memory, and people with Alzheimer’s are known to have fewer of these fast brain waves.”

A new study by MIT researchers finds that an experimental Alzheimer’s treatment involving sound and light stimulation at a frequency of 40 Hz is associated with, “an increase in activity of the brain's own cleanup crew; the glymphatic system,” reports Pandora Dewan for Newsweek. The findings offer an, “exciting, non-invasive potential treatment option for patients with neurological disorders in the future,” Dewan notes.

MIT scientists have found that an experimental treatment for Alzheimer's disease involving sounds and flickering lights appears to “ramp up the brain’s waste disposal networks, which boosts the clearance of beta-amyloid and other toxic proteins that contribute to memory and concentration problems,” reports Clare Wilson for New Scientist. “Once we understand the mechanism, we can probably figure out how to further optimize this whole concept and improve the efficacy,” explains Prof. Li-Huei Tsai.

Cognito Therapeutics, founded by Prof. Ed Boyden and Prof. Li Huei Tsai, has developed a “specialized headset that delivers 40Hz auditory and visual stimulation” to the brain, which could potentially slow down the cognitive decline and neurodegeneration in Alzheimer’s disease, reports William A. Haseltine for Forbes. Prof. Li-Huei Tsai “and her team speculated that if gamma wave activity is reduced in Alzheimer’s disease, perhaps, artificially stimulating the brain may enhance synchronized firing and restore cognition,” writes Haseltine.

Cognito Therapeutics, founded by Prof. Ed Boyden and Prof. Li-Huei Tsai, is using a 40 Hzlight-flickering and auditory headset to help slow the progression of Alzheimer’s and restore cognition, reports William A. Haseltine for Forbes. “A recent pilot clinical trial found that this technology is not only safe and tolerable for home use, but also has a positive impact on reducing symptoms associated with age-related neurodegeneration,” writes Haseltine.

Researchers at MIT and elsewhere have identified key cell types that may protect the brain against Alzheimer’s symptoms, reports Sara Reardon for Nature. “Most Alzheimer’s research has focused on excitatory neurons, which relay electrical signals to activate other neurons,” explains Reardon. “But the authors found that the cells with reelin or somatostatin were inhibitory neurons, which halt neuronal communication. These inhibitory cells might therefore have a previously unknown role in the types of cognitive function that are lost during Alzheimer’s.”

In a new study, researchers at MIT showed that they “were able to interfere with an enzyme typically found to be overactive in the brains of Alzheimer’s patients,” reports Alex Mitchell for The New York Post. After using a peptide to treat the overactive enzyme, they found that “the peptide shows protective effects against loss of neurons and also appears to be able to rescue some of the behavior deficits,” says Prof. Li-Huei Tsai.

Prof. Li-Huei Tsai and Prof. Ed Boyden co-founded Cognito Therapeutics after their research found that gamma waves could help clear amyloid plaques, which are known to appear in Alzheimer’s patients, reports Ryan Cross for The Boston Globe.  “It was the most surprising result I’ve ever got in my life,” says Tsai. “When we published our first paper, most people said, ‘I don’t believe it. This is too good to be true. How can something this simple have this kind of effect?’”

In an excerpt from “Your Brain on Art” published in Fast Company, Susan Magsamen and Ivy Ross spotlight Prof. Li-Huei Tsai research exploring whether gamma oscillations from light and sound could help ease Alzheimer’s symptoms. “Li-Huei believes that increased gamma oscillations in the brain engage many different systems and cell types,” write Magsamen and Ross. “Because of this, the gamma waves may help with amyloid removal.”

Researchers at MIT have found that those with an E4 variant display abnormalities in cholesterol metabolism, reports William A. Haseltine for Forbes. “The MIT team suggest that the disruption of cholesterol metabolism could be a fundamental reason why those with the E4 variant are more likely to develop Alzheimer’s disease symptoms,” writes Haseltine.

An MIT research study suggests that those with the E4 variant of the APOE gene are more likely to develop Alzheimer’s symptoms, reports William A. Haseltine for Forbes. The variant “disrupts how fat molecules are processed in the brain,” writes Haseltine. “It appears that the disruption of these fat molecules could be the fundamental reason why those that contain the E4 variant are more likely to develop Alzheimer’s symptoms.”

Cognito Therapeutics, founded by Prof. Ed Boyden and Prof. Li-Huei Tsai, has secured a large-scale trial to test a new device aimed at treating Alzheimer’s disease, reports Sarah McBride for Bloomberg.

Nature reporter Elie Dolgin writes that a new study by MIT researchers explores the role of the gene variant APOE4 in Alzheimer’s, and finds that the gene is linked with faulty cholesterol processing in the brain, impacting the insulation around nerve cells and potentially causing memory and learning deficits. “The work suggests that drugs that restore the brain’s cholesterol processing could treat the disease,” writes Dolgin. 

USA Today reporter Karen Weintraub spotlights Prof. Li-Huei Tsai’s work studying a potential new approach to treating Alzheimer's disease and “whether certain tones of sound and frequencies of light can help regulate brain waves and help clear our cellular trash, including toxic proteins.” Tsai explains that: “The major difference between this approach and all other approaches is that this approach doesn’t just target one molecule or one pathway or one cell type. This is a holistic approach to take care of the whole system.”

Writing for The Boston Globe, Prof. Li-Huei Tsai underscores the need for the Alzheimer’s research community to “acknowledge the gaps in the current approach to curing the disease and make significant changes in how science, technology, and industry work together to meet this challenge.” Tsai adds: “With a more expansive mode of thinking, we can bridge the old innovation gaps and cross new valleys of discovery to deliver meaningful progress toward the end of Alzheimer’s.”